Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study

TM Govers, D Hessels, V Vlaeminck-Guillem… - Prostate cancer and …, 2019 - nature.com
Background Low specificity of prostate-specific antigen results in a considerable number of
unnecessary prostate biopsies in current practice. SelectMDx® predicts significant prostate …
被引用次数：68 相关文章

Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study

TM Govers, D Hessels… - Prostate cancer …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Low specificity of prostate-specific antigen results in a considerable number of
unnecessary prostate biopsies in current practice. SelectMDx® predicts significant prostate …

Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study

TM Govers, D Hessels… - PROSTATE CANCER …, 2019 - biblio.ugent.be
Background: Low specificity of prostate-specific antigen results in a considerable number of
unnecessary prostate biopsies in current practice. SelectMDx (R) predicts significant …

Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study

TM Govers, JPM Sedelaarll, W van Criekinge… - Prostate Cancer and …, 2019 - hero.epa.gov
Background Low specificity of prostate-specific antigen results in a considerable number of
unnecessary prostate biopsies in current practice. SelectMDx (R) predicts significant …

Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study.

TM Govers, D Hessels… - Prostate Cancer and …, 2018 - europepmc.org
BACKGROUND: Low specificity of prostate-specific antigen results in a considerable
number of unnecessary prostate biopsies in current practice. SelectMDx® predicts …

Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study

TM Govers, D Hessels, V Vlaeminck-Guillem… - PROSTATE CANCER …, 2019 - lib.ugent.be
Background: Low specificity of prostate-specific antigen results in a considerable number of
unnecessary prostate biopsies in current practice. SelectMDx (R) predicts significant …
[PDF] academia.edu

[PDF][PDF] Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study

TM Govers, D Hessels, V Vlaeminck-Guillem… - Prostate Cancer and …, 2019 - academia.edu
Background Low specificity of prostate-specific antigen results in a considerable number of
unnecessary prostate biopsies in current practice. SelectMDx® predicts significant prostate …

[引用][C] Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study

TM Govers, D Hessels, V Vlaeminck-Guillem… - 2019 - repository.ubn.ru.nl
Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative
modeling study Toggle navigation Radboud Repository Toggle navigation View Item Radboud …

Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study

TM Govers, D Hessels… - Prostate Cancer …, 2019 - epub.ub.uni-muenchen.de
Background Low specificity of prostate-specific antigen results in a considerable number of
unnecessary prostate biopsies in current practice. SelectMDx (R) predicts significant …